BISInvivoscribe U.S. WGS Services Intelligence DashboardU.S. whole-genome sequencing services in hematological malignancies, 2025–2036
Library

Business Case & Market Access

Whether U.S. service pricing, reimbursement conditions and adoption barriers support a credible WGS service model.

Service-price benchmark

$XX.XM

Validated benchmark required

Placeholder

Reimbursement position

XX.X

Selected market-access scenario

Placeholder

Adoption-barrier evidence

XX.X

Clinician and laboratory validation required

Placeholder

Commercial viability

XX.X

Validated pricing and access evidence required

Placeholder

Service-price benchmark

Observed U.S. service prices where available

Data available with full BIS Research access.
Y axis:
Price per reported case

U.S. regulatory and reimbursement map

State selection affects access conditions only, never national market values.

Data available with full BIS Research access

Reimbursement pathway

  1. 1CodingApplicable code set for genome-wide testing in hematology.
  2. 2Coverage policyPayer conditions attached to genomic testing in blood cancers.
  3. 3Evidence requirementClinical utility expectations stated by payers.
  4. 4Prior authorisationAdministrative conditions before testing.
  5. 5PaymentRate relative to the cost build-up per case.

Clinician and laboratory adoption barriers

  • Reimbursement uncertainty for genome-wide testing
  • Turnaround time relative to acute clinical decisions
  • Interpretation burden and reporting standardisation
  • Existing validated cytogenetic and panel workflows
  • Capital and informatics investment